Tags

Type your tag names separated by a space and hit enter

Current issues in dengue vaccination.
Curr Opin Infect Dis. 2013 Oct; 26(5):429-34.CO

Abstract

PURPOSE OF REVIEW

Dengue is a global health problem and of concern to travelers and deploying military personnel, with development and licensure of an effective tetravalent dengue vaccine a public health priority. The recent performance of the lead dengue vaccine in a phase 2b efficacy trial underscores dengue vaccine development challenges. This review focuses on current issues in dengue vaccination.

RECENT FINDINGS

The dengue viruses (DENVs) are mosquito-borne flaviviruses transmitted by infected Aedes mosquitoes. Illness manifests across a clinical spectrum with severe disease characterized by intravascular volume depletion and hemorrhage. Recent estimates on the burden of DENV infection determined that there are 390 million dengue infections per year, three times the current estimate by the WHO. There are no licensed antivirals or vaccines to treat or prevent dengue though many are in preclinical or clinical development. DENV illness results from a complex interaction of viral properties and host immune responses. Immunologic complexity, lack of an adequate animal model of disease, absence of an immune correlate of protection, and only partially informative immunogenicity assays are challenging dengue vaccine development efforts.

SUMMARY

Dengue vaccine development efforts have numerous complex challenges to overcome before a well tolerated and effective vaccine is licensed and available. In this review, the authors discuss the current issues in dengue vaccination.

Authors+Show Affiliations

Department of Virology, Walter Reed Army Institute of Research, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

23963259

Citation

Thomas, Stephen J., and Timothy P. Endy. "Current Issues in Dengue Vaccination." Current Opinion in Infectious Diseases, vol. 26, no. 5, 2013, pp. 429-34.
Thomas SJ, Endy TP. Current issues in dengue vaccination. Curr Opin Infect Dis. 2013;26(5):429-34.
Thomas, S. J., & Endy, T. P. (2013). Current issues in dengue vaccination. Current Opinion in Infectious Diseases, 26(5), 429-34. https://doi.org/10.1097/01.qco.0000433310.28771.cc
Thomas SJ, Endy TP. Current Issues in Dengue Vaccination. Curr Opin Infect Dis. 2013;26(5):429-34. PubMed PMID: 23963259.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current issues in dengue vaccination. AU - Thomas,Stephen J, AU - Endy,Timothy P, PY - 2013/8/22/entrez PY - 2013/8/22/pubmed PY - 2014/3/7/medline SP - 429 EP - 34 JF - Current opinion in infectious diseases JO - Curr Opin Infect Dis VL - 26 IS - 5 N2 - PURPOSE OF REVIEW: Dengue is a global health problem and of concern to travelers and deploying military personnel, with development and licensure of an effective tetravalent dengue vaccine a public health priority. The recent performance of the lead dengue vaccine in a phase 2b efficacy trial underscores dengue vaccine development challenges. This review focuses on current issues in dengue vaccination. RECENT FINDINGS: The dengue viruses (DENVs) are mosquito-borne flaviviruses transmitted by infected Aedes mosquitoes. Illness manifests across a clinical spectrum with severe disease characterized by intravascular volume depletion and hemorrhage. Recent estimates on the burden of DENV infection determined that there are 390 million dengue infections per year, three times the current estimate by the WHO. There are no licensed antivirals or vaccines to treat or prevent dengue though many are in preclinical or clinical development. DENV illness results from a complex interaction of viral properties and host immune responses. Immunologic complexity, lack of an adequate animal model of disease, absence of an immune correlate of protection, and only partially informative immunogenicity assays are challenging dengue vaccine development efforts. SUMMARY: Dengue vaccine development efforts have numerous complex challenges to overcome before a well tolerated and effective vaccine is licensed and available. In this review, the authors discuss the current issues in dengue vaccination. SN - 1473-6527 UR - https://www.unboundmedicine.com/medline/citation/23963259/Current_issues_in_dengue_vaccination_ L2 - https://doi.org/10.1097/01.qco.0000433310.28771.cc DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.